Drug Profile

EM 101

Alternative Names: EM-101; EM101-Enterome

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enterome
Class Anti-inflammatories; Antihyperglycaemics; Bacterial proteins; Peptidomimetics
Mechanism of Action Interleukin 10 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

No development reported Inflammatory bowel diseases; Type 2 diabetes mellitus

28 Aug 2024 No recent reports of development identified for research development in Type-2-diabetes-mellitus in France
28 Jul 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in France
30 Jul 2020 Early research in Type 2 diabetes mellitus in France (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com